Adamis Pharmaceuticals Corp. (ADMP) Given a $10.00 Price Target by Maxim Group Analysts
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) received a $10.00 price target from equities researchers at Maxim Group in a research note issued on Monday. The brokerage presently has a a “buy” rating on the specialty pharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 210.56% from the stock’s current price.
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) opened at 3.22 on Monday. The company’s market cap is $67.25 million. Adamis Pharmaceuticals Corp. has a 1-year low of $2.50 and a 1-year high of $10.98. The firm’s 50-day moving average is $2.84 and its 200 day moving average is $4.98.
Hedge funds have recently added to or reduced their stakes in the company. BlackRock Fund Advisors raised its stake in Adamis Pharmaceuticals Corp. by 24.7% in the second quarter. BlackRock Fund Advisors now owns 49,806 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 9,868 shares during the last quarter. Walleye Trading LLC raised its stake in Adamis Pharmaceuticals Corp. by 118.1% in the second quarter. Walleye Trading LLC now owns 275,078 shares of the specialty pharmaceutical company’s stock worth $770,000 after buying an additional 148,966 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Adamis Pharmaceuticals Corp. by 21.8% in the second quarter. Vanguard Group Inc. now owns 335,814 shares of the specialty pharmaceutical company’s stock worth $940,000 after buying an additional 60,197 shares during the last quarter. Institutional investors and hedge funds own 9.70% of the company’s stock.
Adamis Pharmaceuticals Corp. Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp. and related companies with MarketBeat.com's FREE daily email newsletter.